Systems, methods, and kits for diagnostics and treatment of viral respiratory infection

Abstract

Systems, methods, and kits for treating, preventing, and diagnosing viral infection using an androgen mediated pathway are described. Additionally, methods and kits for guiding treatment of viral respiratory disease are described by a method for testing for polymorphisms in the androgen receptor gene. Further, systems and methods for treatment of viral respiratory disease with various anti-androgens is detailed. Finally, systems, methods, and kits for treating, preventing, and diagnosing SARS-CoV-2 (COVID-19) are presented.

1 . A composition for treatment of a viral respiratory infection, the composition comprising an anti-androgen, wherein the anti-androgen is marijuana, cannabinoids or a combination thereof. 
     
     
         2 . (canceled) 
     
     
         3 . The composition of  claim 1 , wherein the composition is formulated to facilitate administration of the composition topically to the skin, nasally, sub-lingually orally, by injection, via inhalation, or ocular application. 
     
     
         4 . The composition of  claim 1 , wherein the viral respiratory infection is any one or combination of coronavirus, influenza, influenza A, influenza B, SARS-CoV-1, SARS-CoV-2, MFRS-CoV, or rhinoviruses. 
     
     
         5 . (canceled) 
     
     
         6 . The composition of  claim 1 , wherein the composition is formulated for use as a treatment of the viral respiratory infection, a therapy for the viral respiratory infection, a prophylactic for the viral respiratory infection, and/or a preventive measure for contracting the viral respiratory infection. 
     
     
         7 . (canceled) 
     
     
         8 . A method of treating a patient having or suspected of having a viral respiratory infection, the method comprising:
 administering a composition according to  claim 1  to the patient.   
     
     
         9 . (canceled) 
     
     
         10 . The method of  claim 8 , wherein the administration of the composition involves any one or combination of topical application to the skin, nasal application, sub-lingual application, oral application, via injection, via inhalation, or ocular application. 
     
     
         11 . The method of  claim 8 , wherein the viral respiratory infection is any one or combination of coronavirus, influenza, influenza A, influenza B, SARS-CoV-1, SARS-CoV-2, MERS-CoV or rhinoviruses. 
     
     
         12 . The method of  claim 8 , wherein the composition is used as a treatment for the viral respiratory infection, a therapy for the viral respiratory infection, a prophylactic for the viral respiratory infection, and/or a preventive measure for contracting the viral respiratory infection. 
     
     
         13 . The method of  claim 8 , wherein the treatment involves administering the composition as a treatment for the viral respiratory infection and/or a prophylactic for the viral respiratory infection before, during, and/or after the patient is first diagnosed with the viral respiratory infection and/or before, during, and/or after the patient is hospitalized due to the viral respiratory infection. 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . The method of  claim 8 , wherein administering the composition involves administering an oral cannabidiol at 1-30/mg/Kg/day. 
     
     
         24 . The method of  claim 8 , wherein administering the composition involves administering an oral cannabidiol at 1-10/mg/Kg/day. 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . (canceled)